| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1023880af10dbe26a57dfb1cb687f92d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18334
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55594
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18534
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18371 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
| filingDate |
2014-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11f5f5aa93f945dd9644325a90e19781
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6ee91c5aef269425045a7cad8be43bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd398e5d7c0f572d083550c9da73a7f3 |
| publicationDate |
2018-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9999663-B2 |
| titleOfInvention |
Immunogenic formulation containing recombinant live BCG that express antigens of metapneumovirus (hMPV), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use |
| abstract |
The present invention relates to an immunogenic formulation to be used in mammals against human Metapneumovirus (hMPV), consisting of a lyophilisate of 1×10 9 ufc/ml of recombinant BCG that expresses the viral protein P of hMPV (of genogroups A1, A2, B1 and B2). The vaccine is derived from the full or partial product of the P gene of hMPV, capable of being used, stabilised and administered in solution without requiring adjuvants. The preparation can also contain combinations of the aforementioned formulations. The formulation is stabilised by means of lyophilisation (conservation range of between 4° C. and 8° C.) in order to be subsequently reconstituted in an adjuvant-free saline solution prior to use. |
| priorityDate |
2013-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |